● ● ● ● ● ● ● ● ● Interactions● ● ● ● ● ● macrolide antibioticsdepressantsProlongation of QT intervalAgranulocytosis Weight g a i n Decreased serum concentrations of haloperidol, worsening schizophrenic symptoms, and tardive dyskinesia with con-comitant use of Decreased therapeutic effects of haloperidol with Extrapyramidal symptoms Increased plasma concentrations when administered with drugs that inhibit CYP3A enzymes (effects, fever, leukocytosis, and increased serum enzymes.Additive CNS depression with alterations in consciousness, encephalopathy, extrapyramidal Coadministration of haloperidol and flGynecomastia Additive hypotension with Tardive dyskinesia Decreased therapeutic effects of haloperidol with Reduction of seizure threshold azepineNeuroleptic malignant syndrome uvoxamine; increased effects of ) anticholinergic agents) and CYP1A2 enzymes (antihypertensivescarbamazepinealcohol Antipsychotic Agents azole antifungal agents; lithiumor other may result in rifamycinsfl uoxetine; carbam-●CNS^479
Children (3 to 12 years; weight range 15 to 40 kg): ● ● HALOPERIDOLRoute and Dosage Control of Acutely Agitated Schizophrenic Patient:Psychotic Disorders:(e.g., Additive effects with other drugs that prolong QT interval severe hypotension.Concurrent use with rhythmic agents100 mg/day. not to exceed 100 mg/day. 2 or 3 times a day. Some patients may require dosages up to apeutic effect is obtained. Administer in 2 or 3 divided doses. ments at 5- to 7-day intervals up to 0.15 mg/kg/day or until ther-(Severe symptoms or chronic or resistant patients): geriatric or debilitated patients):0.5 mg/day (25 to 50 mcg/kg/day). May increase in 0.5 mg incre-IM (lactate): phenothiazines^ (Haldol) 2 to 5 mg. May be repeated every 1 to 8 hours, ) epinephrine^ , Adults: tricyclic antidepressants, antiar- 0.5 to 2 mg 2 or 3 times a day. PO: or dopamine(Moderate symptoms or may result in Initial dose: 3 to 5 mg Adults:
2 2506_Ch28_472-501.indd 1479 506 Ch 28 472 - 501 .indd 1479 1 10/1/10 9:40:06 AM 0 / 1 / 10 9 : 40 : 06 AM